PURPOSE: The incorporation of doxorubicin in long-circulating sterically stabilized liposomes (SSL-DXR) alters the pharmacokinetics and biodistribution of doxorubicin and therefore has the potential to alter the pharmacologic properties of doxorubicin. Previously, we showed that repetitive administration of SSL-DXR alters tumor vascular permeability. EXPERIMENTAL DESIGN: Here, we investigated the effect of weekly i.v. injections of SSL-DXR on plasma pharmacokinetics and drug biodistribution in the orthotopic 9L rat brain tumor model. RESULTS AND CONCLUSIONS: The pharmacokinetics of free doxorubicin (5.67 mg/kg) did not change with repeat dosing. In contrast, drug concentrations in plasma and brain tumor increased and deposition in liver and spleen decreased after administration of the second of two weekly doses of SSL-DXR. Noncompartmental analysis and descriptive pharmacokinetic models were created to test hypotheses relating to the mechanisms responsible for alterations in SSL-DXR deposition. The analysis suggested that weekly administration of SSL-DXR significantly (P < 0.05) decreased the plasma elimination rate of SSL-DXR (34%) and decreased drug deposition in liver (2-fold) and spleen (3.5-fold). The pharmacokinetic model that best captured the observed 2.5-fold increase in tumor uptake of SSL-DXR mediated by repeat dosing was one that hypothesized that the rates of drug influx/efflux into tumor were increased by the first dose of SSL-DXR. Models that accounted only for residual drug deposited in the tissue or blood by the first weekly injection provided inferior fits to the data. Thus, the effects of repetitive dosing on SSL-DXR deposition in tumor are consistent with a treatment-mediated alteration of tumor vascular permeability.
PURPOSE: The incorporation of doxorubicin in long-circulating sterically stabilized liposomes (SSL-DXR) alters the pharmacokinetics and biodistribution of doxorubicin and therefore has the potential to alter the pharmacologic properties of doxorubicin. Previously, we showed that repetitive administration of SSL-DXR alters tumor vascular permeability. EXPERIMENTAL DESIGN: Here, we investigated the effect of weekly i.v. injections of SSL-DXR on plasma pharmacokinetics and drug biodistribution in the orthotopic 9L ratbrain tumor model. RESULTS AND CONCLUSIONS: The pharmacokinetics of free doxorubicin (5.67 mg/kg) did not change with repeat dosing. In contrast, drug concentrations in plasma and brain tumor increased and deposition in liver and spleen decreased after administration of the second of two weekly doses of SSL-DXR. Noncompartmental analysis and descriptive pharmacokinetic models were created to test hypotheses relating to the mechanisms responsible for alterations in SSL-DXR deposition. The analysis suggested that weekly administration of SSL-DXR significantly (P < 0.05) decreased the plasma elimination rate of SSL-DXR (34%) and decreased drug deposition in liver (2-fold) and spleen (3.5-fold). The pharmacokinetic model that best captured the observed 2.5-fold increase in tumor uptake of SSL-DXR mediated by repeat dosing was one that hypothesized that the rates of drug influx/efflux into tumor were increased by the first dose of SSL-DXR. Models that accounted only for residual drug deposited in the tissue or blood by the first weekly injection provided inferior fits to the data. Thus, the effects of repetitive dosing on SSL-DXR deposition in tumor are consistent with a treatment-mediated alteration of tumor vascular permeability.
Authors: T D Madden; P R Harrigan; L C Tai; M B Bally; L D Mayer; T E Redelmeier; H C Loughrey; C P Tilcock; L W Reinish; P R Cullis Journal: Chem Phys Lipids Date: 1990-03 Impact factor: 3.329
Authors: E T Dams; P Laverman; W J Oyen; G Storm; G L Scherphof; J W van Der Meer; F H Corstens; O C Boerman Journal: J Pharmacol Exp Ther Date: 2000-03 Impact factor: 4.030
Authors: P Laverman; M G Carstens; O C Boerman; E T Dams; W J Oyen; N van Rooijen; F H Corstens; G Storm Journal: J Pharmacol Exp Ther Date: 2001-08 Impact factor: 4.030
Authors: P Laverman; A H Brouwers; E T Dams; W J Oyen; G Storm; N van Rooijen; F H Corstens; O C Boerman Journal: J Pharmacol Exp Ther Date: 2000-06 Impact factor: 4.030
Authors: Jeong Yeon Kang; Mathew Eggert; Shravanthi Mouli; Ibrahim Aljuffali; Xiaoyu Fu; Ben Nie; Amy Sheil; Kendall Waddey; Charlie D Oldham; Sheldon W May; Rajesh Amin; Robert D Arnold Journal: Pharm Res Date: 2014-08-27 Impact factor: 4.200
Authors: Tista Roy Chaudhuri; Ninfa L Straubinger; Rosemarie F Pitoniak; Bonnie L Hylander; Elizabeth A Repasky; Wen Wee Ma; Robert M Straubinger Journal: Mol Cancer Ther Date: 2015-10-29 Impact factor: 6.261
Authors: Rong Zhou; Richard V Mazurchuk; Judith H Tamburlin; John M Harrold; Donald E Mager; Robert M Straubinger Journal: J Pharmacol Exp Ther Date: 2009-10-27 Impact factor: 4.030
Authors: Shailendra Joshi; Johann R N Cooke; Darren K W Chan; Jason A Ellis; Shaolie S Hossain; Rajinder P Singh-Moon; Mei Wang; Irving J Bigio; Jeffrey N Bruce; Robert M Straubinger Journal: Drug Deliv Transl Res Date: 2016-06 Impact factor: 4.617